Go to ...

Nordens Ekonomi Norge

RSS Feed

18. november 2018

Corvus Pharmaceuticals Announces Updated Results from Ongoing Clinical Studies of Lead Programs, CPI-444 and CPI-006, at SITC 33rd Annual Meeting


Euroinvestor.com A/S Euroinvestor.com A/S



CPI-444 demonstrated prolonged survival in patients with refractory renal cell carcinoma both as a monotherapy and in combination with atezolizumab




Novel adenosine gene signature biomarker assoc..

More Stories From

Do NOT follow this link or you will be banned from the site!
Read previous post:
Larson Electronics Releases 25W Handheld LED Hunting Spotlight with 1000’ Light Beam

KEMP, Texas, Nov. 10, 2018 (GLOBE NEWSWIRE) -- Larson Electronics, a Texas-based company with over 40 years of experience spearheading...

Close